SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Bristol Myers Squibb in NJ/iStock, arlut
Policy
FDA Accepts Priority Review of BMS Opdivo, Chemo in Bladder Cancer Race
The regulator has accepted Bristol Myers Squibb’s Opdivo and the chemotherapy cisplatin for priority review in patients with unresectable metastatic urothelial carcinoma, as well as Merck and Seagen’s first-line combo.
December 6, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Roche Diagnostics building in California
Drug Development
Roche Gets Phase III Breast Cancer Victory for Inavolisib Combo
A combination of Roche’s investigational treatment with Ibrance and fulvestrant met its primary endpoint of progression-free survival in the first-line setting in treating PIK3CA-mutated breast cancer.
December 5, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Financing concept/Getty Images
Amgen-Backed Seismic Secures $121M in Series B Funding
Mass.-based Seismic Therapeutic secured a new investor in Bessemer Venture Partners and $121 million in its Series B round as it looks to push its two lead candidates into the clinic.
December 4, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: AstraZeneca signage at its office in Sweden
Business
AstraZeneca to Spend $247M in Collaboration with AI Discovery Outfit Absci
In the latest example of big pharma entering AI collaborations or using AI-based tools, AstraZeneca’s deal with Absci will aim to produce an oncology candidate.
December 4, 2023
 · 
2 min read
 · 
Tyler Patchen
Niels Wenstedt/BSR Agency/Getty Images
Policy
EMA Requests More Data from GLP-1 Drugmakers in Suicidal Ideation, Self-Harm Probe
The European Medicines Agency is seeking additional information from the makers of GLP-1 drugs as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class.
December 4, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage at its world headquarters in New York
Drug Development
Pfizer Nixes Twice-Daily Oral GLP-1 Candidate After High Rates of Side Effects
While Pfizer’s oral GLP-1 candidate met its primary endpoint in a Phase IIb obesity trial, twice-daily dosing of danuglipron resulted in high rates of adverse events including nausea, vomiting and diarrhea.
December 1, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: AbbVie Corporate Office/iStock, vzphotos
Drug Development
AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval
The company’s investigational c-Met protein directed antibody-drug conjugate showed a “compelling” overall response rate in patients with previously treated non-small cell lung cancer.
December 1, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Astellas' Americas headquarters in Illin
Drug Development
Astellas Touts Phase III Data for Menopause Drug, Eyes European Reimbursement
The company is hoping the topline results for Veozah, which won FDA approval in May, will support health technology assessments for reimbursement negotiations in Europe.
December 1, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Businessmen shaking hands after closing a deal
Policy
Samsung Bioepis, J&J Ink Settlement and License Deal for Stelara Biosimilar
The two companies have settled all pending U.S. patent litigation, clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of Stelara.
November 30, 2023
 · 
2 min read
 · 
Tyler Patchen
Update: AbbVie headquarters building in California
Deals
AbbVie Buys ImmunoGen in $10B Deal, Gains Access to ADC for Ovarian Cancer
Facing the loss of Humira revenues from biosimilar competition, AbbVie is looking to grow its pipeline by acquiring ImmunoGen and its antibody-drug conjugate Elahere, which was granted FDA accelerated approval last year.
November 30, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Man holding a cell phone in front of com
Verve Stock Takes a Hit on $148M Offering to Public, Lilly
After Verve Therapeutics recently announced gene editing therapy results, the company is offering up its stock to the public and Eli Lilly. However, the stock was down 13% Wednesday on the news.
November 29, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Capsules in a production line at a pharm
Drug Development
CDMOs Face Headwinds in 2023, Look to Slow Recovery
BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.
November 29, 2023
 · 
6 min read
 · 
Tyler Patchen
Deals
Deals, Dupixent and GLP-1 drug shortages
This week on The Weekly we talk struggles with ⁠GLP-1 drug shortages⁠ and what that might mean for Novo and Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠⁠Dupixent⁠⁠⁠ in COPD. Plus, Merck ⁠buys Caraway⁠, Beigene’s ⁠deal⁠ with Ensem, ⁠ups⁠ and ⁠downs⁠ for Flagship.
November 29, 2023
 · 
1 min read
 · 
Lori Ellis
Facade of the FDA's office in Maryland
Policy
FDA Launches Probe of Malignancies Linked to CAR-T Therapies
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
November 28, 2023
 · 
3 min read
 · 
Tyler Patchen
Pictured: Red line graph showing a downward trend/
Drug Development
Argenx’s Vyvgart Fails to Hit Primary, Secondary Endpoints in Phase III Trial
The Dutch biotech’s stock dropped about 10% Tuesday morning after the company reported that its injectable Vyvgart Hytrulo missed the primary and secondary endpoints in an immune thrombocytopenia study.
November 28, 2023
 · 
2 min read
 · 
Tyler Patchen
Load More